Liquidia Announces Special Meeting Date to Approve Proposed Acquisition of RareGen, LLC - Seite 2

The proposed merger is subject to customary closing conditions, including approval of the merger by the stockholders of Liquidia Technologies. After the close of the transaction, Liquidia Corporation common stock is expected to trade under the ticker symbol “LQDA” on the Nasdaq Capital Market as the successor to Liquidia Technologies.

The final proxy statement/prospectus filed with the SEC on September 16, 2020 contains important information about the proposed acquisition, the Agreement and Plan of Merger and the proposals to be considered at the special meeting and is available (here) on the investor page of Liquidia’s website.

About Liquidia
Liquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. Liquidia is headquartered in Research Triangle Park, NC. For more information, please visit www.liquidia.com.

About RareGen
RareGen, LLC is a portfolio company of PBM Capital Group, a healthcare investment firm. RareGen provides strategy, investment, and commercialization for rare disease pharmaceutical products. RareGen has a national sales force focused on cardiology and pulmonology specialties.

Important Information About the Transaction and Where to Find It

In connection with the proposed merger transaction, the Company and Liquidia Corporation have filed documents with the  SEC, including the filing by Liquidia Corporation of a registration statement on Form S-4, which was declared effective on September 16, 2020, and a final proxy statement/prospectus, and the Company intends to mail to its stockholders a proxy statement regarding the proposed merger transaction to its stockholders that will also constitute a prospectus of the Company. This document is not a substitute for the proxy statement/prospectus or registration statement or any other document which the Company or Liquidia Corporation have filed with the SEC. Investors and security holders of the Company and RareGen are urged to read the registration statement, the proxy statement/prospectus and any other relevant documents, as well as any amendments or supplements to these documents, carefully and in their entirety because they will contain important information. Investors and security holders may obtain free copies of the registration statement and the proxy statement/prospectus and other documents filed with the SEC by the Company through the website maintained by the SEC at www.sec.gov or by contacting the investor relations department of the Company  at the following: